Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × resminostat × Lymphoid × Clear all
NCT02953301 2024-08-30

RESMAIN

4SC AG

Phase 2 Completed
201 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01037478 2014-01-16

SAPHIRE

4SC AG

Phase 2 Completed
37 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡